Key Takeaways
  • Zepbound is the first drug that’s been approved by the FDA to treat obstructive sleep apnea (OSA).
  • People with an OSA diagnosis and a BMI of 27 or higher may be prescribed Zepbound.
  • Zepbound is a GLP-1 that may help lessen OSA symptoms by treating obesity as an underlying disorder.
  • Some insurance providers including Medicare Part D may cover Zepbound costs.

A poll done in 2024 showed that roughly 12% of adults have taken a GLP-1 agonist, a type of drug used for weight loss, diabetes, and other health conditions . In December 2024, a GLP-1 medication called Zepbound was approved to treat moderate to severe obstructive sleep apnea (OSA). This is the first time that the Food and Drug Administration (FDA) has approved a drug for OSA .

OSA is a common sleep-related breathing disorder that can have serious symptoms and health risks when left untreated . Currently, continuous positive airway pressure (CPAP) therapy is the most common and effective OSA treatment, but not everyone with OSA can use a CPAP machine .

Two recent studies show that treating OSA with Zepbound may be a worthwhile consideration for some people who have the condition .

What Is Zepbound?

Zepbound is an injectable weight loss drug. Its generic name is tirzepatide. The pharmaceutical company that manufactures Zepbound also makes Mounjaro, which uses tirzepatide as an active ingredient. The FDA has approved Mounjaro for type 2 diabetes and Zepbound for OSA.

The FDA approved Zepbound for sleep apnea for people with obesity and a body mass index (BMI) of 27 or more. They also approved it for those who have those with a BMI of 30 or higher. OSA is a common symptom of obesity, and Zepbound works to improve obesity ailments by addressing weight loss. The FDA indicates that people treating OSA with Zepbound should also diet and exercise to get the best results.

How Does Zepbound Help With Sleep Apnea?

Zepbound can be used as a sleep apnea treatment by helping users lose weight. Obesity and neck circumference are contributing factors to OSA. Losing weight and neck mass helps ease the pressure that’s placed on a person’s upper airway, which can in turn decrease how often their breathing stops during sleep.

During a randomized, controlled study, the average participant lost between 34 and 58 pounds and stopped breathing 20 to 23 fewer times during an hour of sleep than in their baseline results before taking the drug .

Tirzepatide, the active ingredient in Zepbound, promotes weight loss by mimicking a naturally occurring gut hormone . It sends signals to the body that suppress a person’s appetite so they feel less hungry and more full, which results in consuming fewer calories. 

Unlike CPAP therapy, Zepbound doesn’t treat the acute symptoms of OSA, like upper airway collapse, but instead targets weight loss as an underlying symptom of OSA.

What Are the Side Effects of Zepbound?

Common Zepbound side effects include :

  • Nausea
  • Vomiting
  • Constipation
  • Stomach pain
  • Acid reflux
  • Injection site reactions
  • Drowsiness
  • Hairloss

There are other less common but serious side effects associated with Zepbound. You should always talk to your doctor about any concerns you have about possible medication interferences or any side effects that develop. People who are breastfeeding, pregnant, or intending to become pregnant should also consult their physicians before taking Zepbound.

How Do You Use Zepbound for Sleep Apnea?

Zepbound is an injectable medication that should be taken once a week. It’s available as a single-dose injectable pen. There is no mixing required. Zepbound can be injected into the stomach, thigh, or arm with rotation of injection sites recommended. 

Zepbound is usually started at the lowest dose of 2.5mg and then is gradually increased to 5mg. A medical provider may decide to increase dosages by 2.5 mg to a maintenance dose of 5, 10, or 15 mg. The maximum Zepbound dose is 15 mg.

Zepbound should be stored in the refrigerator and pens or syringes need to be properly disposed of in a sharps container. To maintain the weight loss needed to help with OSA symptoms, Zepbound users should exercise regularly and consume fewer calories than they did before starting Zepbound. 

Is Zepbound Right for You?

Zepbound is an approved weight loss drug for people with a BMI of 30 or higher and as an OSA medication for people with a BMI of 27 or higher. If you fall into either of those categories, speak with your physician to find out if Zepbound is right for your needs.

Frequently Asked Questions

Will insurance cover Zepbound for sleep apnea?

Some insurance plans cover Zepbound for sleep apnea. You’ll need to check with your specific insurance provider to learn whether or not Zepbound costs are covered. Zepbound is currently approved to treat obesity and OSA. 

Many insurance providers still do not cover GLP-1 drugs including Zepbound for weight loss, but some will offer coverage for Zepbound for sleep apnea. You’ll likely need an OSA diagnosis to qualify for insurance coverage. You may also need to get prior authorization, which your physician can submit for you. Check with your physician and insurance provider to get more details that are specific to your plan.

Does Medicare cover Zepbound for sleep apnea?

Though Medicare does not yet cover Zepbound for weight loss, Medicare Part D may cover Zepbound for sleep apnea. Medicare Part D is optional, additional coverage that helps with the cost of brand name drugs. 

Like other insurance plans, Medicare Part D has a monthly premium and costs can vary. The drug deductible for 2026 is $615 and the out-of-pocket prescription drug max is $2,100. Keep in mind that though a plan may cover Zepbound for sleep apnea, you’ll need to make sure to choose a pharmacy that’s in network.

Is Zepbound a replacement for CPAP?

Zepbound and CPAP therapy target sleep apnea symptoms in two different ways. Though they can complement one another, they are not replacements for each other. CPAP therapy uses pressurized air to keep breathing passages open while you sleep, while Zepbound works to reduce body weight and treat obesity as an underlying cause of sleep apnea. 

While Zepbound and CPAP have different end goals, one study shows both CPAP users and non-CPAP users can find significant symptom relief by using Zepbound. Not everyone tolerates CPAP therapy well, so those who’ve tried and failed to adhere to PAP therapy may want to ask their physicians about using Zepbound for OSA symptoms.

How soon can I expect sleep apnea improvement?

Though there isn’t currently a cut and dry cure for sleep apnea, during Zepbound trials , participants saw significant improvement in sleep apnea symptoms after 52 weeks, or after some weight was lost. Physicians prescribe Zepbound in incremental doses on a 4-week schedule. It may take up to 24 weeks to reach your maintenance dose. 

Still have questions? Ask our community!

Join our Sleep Care Community — a trusted hub of sleep health professionals, product specialists, and people just like you. Whether you need expert sleep advice for your insomnia or you’re searching for the perfect mattress, we’ve got you covered. Get personalized guidance from the experts who know sleep best.

References
10 Sources

  1. Montero A, Sparks G, Presiado M, Hamel L. KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs | KFF. KFF. Published May 10, 2024. https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/

    https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/
  2. FDA News Release. (2024, December 20). FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food & Drug Administration.

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
  3. Kline, Lewis R. (2024, October 9). Clinical presentation and diagnosis of obstructive sleep apnea in adults. UpToDate.

    https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-obstructive-sleep-apnea-in-adults
  4. Cao MT, Sternbach JM, Guilleminault C. Continuous positive airway pressure therapy in obstuctive sleep apnea: benefits and alternatives. Expert Rev Respir Med. 2017;11(4):259-272. doi:10.1080/17476348.2017.1305893

    https://pubmed.ncbi.nlm.nih.gov/28287009/
  5. Atul Malhotra, M.D., Ronald R. Grunstein, M.D., Ph.D., Ingo Fietze, M.D., Terri E. Weaver, Ph.D., Susan Redline, M.D., M.P.H., Ali Azarbarzin, Ph.D., Scott A. Sands, Ph.D. (2024, June 21). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205.

    https://www.nejm.org/doi/full/10.1056/NEJMoa2404881
  6. FDA Approves Lilly’s ZepboundTM (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems | Eli Lilly and Company. Eli Lilly and Company. Published 2022. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight

    https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
  7. Farzam K, Patel P. Tirzepatide. [Updated 2024 Feb 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK585056/

    https://www.ncbi.nlm.nih.gov/books/NBK585056/
  8. Zepbound® (tirzepatide) Injection. Lilly.com. Published 2024. https://zepbound.lilly.com/weight/obesity-excess-weight

    https://zepbound.lilly.com/weight/obesity-excess-weight
  9. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration. Published December 20, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea